Biophytis Delays Yearly Report Due to Financing Efforts

Biophytis ( (BPTSY) ) has released a notification of late filing.

Biophytis, a biotechnology company, has filed a Form 12b-25 to notify the delay in submitting its Form 20-F (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the company’s recent efforts to secure financing through a private placement, which required significant time and resources, impacting their ability to finalize financial statements and disclosures on time. Biophytis anticipates filing the delayed report within the 15-day extension period allowed by the SEC. The company does not expect any significant changes in its financial results for the reported period. Biophytis is actively working to comply with all necessary requirements, as indicated by the signature of Stanislas Veillet, Chief Executive Officer and Director.

Spark’s Take on BPTSY Stock

According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.

Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.

To see Spark’s full report on BPTSY stock, click here.

More about Biophytis

YTD Price Performance: -55.41%

Average Trading Volume: 11

Technical Sentiment Signal: Buy

Current Market Cap: $3.98M

For a thorough assessment of BPTSY stock, go to TipRanks’ Stock Analysis page.